STAT2 and hepatocellular carcinoma: Notably, Icarisitin, as a therapeutic agent for HCC, was found to promote the expression of FAM99A, thereby blocking the JAK1/STAT2 pathway that mediates HCC cell proliferation and GLUT3‐related glycolysis [31].